

10/562023

IAP20 Rec'd PCT/PTO 20 DEC 2005
PATENT

Attorney Docket No. 82493
Customer Number 23685

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
MATTHIAS SCHUSTER)	
)	
Serial No.: Unassigned)	Group Art Unit: Unknown
)	
I.A. Filed: June 17, 2004)	Examiner: Unknown
)	
For: METHOD FOR INVESTIGATING)	Confirmation Number: Unknown
CYTOSINE METHYLATION IN)	
DNA SEQUENCES BY MEANS OF)	
TRIPLEX-FORMING OLIGOMERS))	

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant discloses the following information:

1. Huang et al., "Triplex formation by oligonucleotides containing novel deoxycytidine derivatives," Nucleic Acids Research, 24(13):2606-13 (1996);
2. Huang et al., "Triplex Formation by an Oligodeoxyribonucleotide Containing N⁴-(6-Aminopyridinyl)-2'-deoxycytidine," J. Am. Chem. Soc., 115:10456-7 (1993); and
3. Xodo et al., "Effect of 5-Methylcytosine on the Structure and Stability of DNA. Formation of Triple-Stranded Concatenamers by Overlapping Oligonucleotides," Journal of Biomolecular Structure & Dynamics, 11(4):703-20 (1994).

Copies of above document nos. 1-3 are provided with this paper. In addition, the above documents are listed on the enclosed PTO Form PTO/SB/08B. Applicant respectfully requests that

10/562023

IAP20 Rec'd 10/27/05 20 DEC 2005

the Examiner consider the enclosed documents and evidence that consideration by making appropriate notations on the enclosed forms.


This submission does not represent that a search has been made or that no better prior art exists and does not constitute an admission that the enclosed documents constitute "prior art."

Applicant reserves the right to take appropriate action to establish the patentability of the disclosed invention over the enclosed documents, should the documents be applied against the claims of the present invention.

If there are any fees due in connection with the filing of this paper that are not accounted for, the Examiner is authorized to charge the fees to our Deposit Account No. 11-1755. If a fee is required for an extension of time under 37 C.F.R. 1.136 that is not accounted for already, such an extension of time is requested and the fee should also be charged to our Deposit Account.

Respectfully submitted,

Kriegsman & Kriegsman

By: 

Edward M. Kriegsman
Reg. No. 33,529
665 Franklin Street
Framingham, MA 01702
(508) 879-3500

Dated: December 20, 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	Unassigned		
		Filing Date	June 17, 2004		
		First Named Inventor	Matthias Schuster		
		Art Unit	Unknown		
		Examiner Name	Unknown		
Sheet		of		Attorney Docket Number	82493

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Huang et al., "Triplex formation by oligonucleotides containing novel deoxycytidine derivatives," Nucleic Acids Research, 24(13):2606-13 (1996)	
		Huang et al., "Triplex Formation by an Oligodeoxyribonucleotide Containing N4-(6-Aminopyridinyl)-2'-deoxycytidine, J. Am. Chem. Soc., 115:10456-7 (1993)	
		Xodo et al., Journal of Biomolecular Structure & Dynamics, 11(4):703-20 (1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.